XSHE
300204
Market cap1.37bUSD
Oct 09, Last price
20.66CNY
1D
1.97%
1Q
-14.66%
Jan 2017
16.53%
IPO
203.99%
Name
Staidson (Beijing) Biopharmaceuticals
Chart & performance
P/E
—
P/S
42.55
EPS
—
Div yield, %
—
Shrs. gr., 5y
0.51%
Rev. gr., 5y
-17.73%
Revenues
220m
-32.20%
Net income
0
P
CFO
0
P
Dividend
May 17, 20190.66807 CNY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Staidson (Beijing) BioPharmaceuticals Co., Ltd. is a Chinese biopharmaceutical company that specializes in the entire lifecycle of therapeutic drugs, from research and development to production and market distribution. Their product portfolio encompasses a variety of drug types, including advanced protein-based medicines like therapeutic monoclonal antibodies, innovative gene and cell therapies, and conventional chemical pharmaceuticals. The company's primary therapeutic areas address conditions related to the nervous system, infectious diseases, gastrointestinal health, the urinary system, and autoimmune disorders. Notably, Staidson has established a strategic partnership with Pivotal S.L. to conduct clinical trials in Europe for BDB-001, a monoclonal anti-C5a antibody, aimed at treating patients with severe, progressive COVID-19 caused by the SARS-CoV-2 virus. Founded in 2002, the company's headquarters are located in Beijing, China.
Key people
Rongqin Zhang
General Manager · since 2015
Yanfang Sun
Chief Engineer · since 2015
Li'na Ma
Secretary of the Board, Deputy General Manager · since 2012
Zhenqi Gu
Director · since 2002
Maowu Guo
Director · since 2009
Lixin Jiang
Deputy General Manager, Director
Zhiwen Zhou
Chairman of the Board · since 2012
Songsheng Wu
Independent Director · since 2011
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2023‑00 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | |||||||||||
Revenues | |||||||||||
Cost of revenue | |||||||||||
Unusual Expense (Income) | |||||||||||
NOPBT | |||||||||||
NOPBT Margin | |||||||||||
Operating Taxes | |||||||||||
Tax Rate | |||||||||||
NOPAT | |||||||||||
Net income | |||||||||||
Dividends | |||||||||||
Dividend yield | |||||||||||
Proceeds from repurchase of equity | |||||||||||
BB yield | |||||||||||
| Debt | |||||||||||
Debt current | |||||||||||
Long-term debt | |||||||||||
Deferred revenue | |||||||||||
Other long-term liabilities | |||||||||||
Net debt | |||||||||||
| Cash flow | |||||||||||
Cash from operating activities | |||||||||||
CAPEX | |||||||||||
Cash from investing activities | |||||||||||
Cash from financing activities | |||||||||||
FCF | |||||||||||
| Balance | |||||||||||
Cash | |||||||||||
Long term investments | |||||||||||
Excess cash | |||||||||||
Stockholders' equity | |||||||||||
Invested Capital | |||||||||||
ROIC | |||||||||||
ROCE | |||||||||||
| EV | |||||||||||
Common stock shares outstanding | |||||||||||
Price | |||||||||||
Market cap | |||||||||||
EV | |||||||||||
EBITDA | |||||||||||
EV/EBITDA | |||||||||||
Interest | |||||||||||
Interest/NOPBT | |||||||||||